Suitability of Yin Yang 1 Transcript and Protein Levels for Biomarker Studies in B Cell Non-Hodgkin Lymphoma

Overview

Journal Biomark Res

Publisher Biomed Central

Date 2018 Mar 23

PMID 29564133

Citations 6

Authors

Jessica Arribas Arranz

Dalia Nilufar Winter

Hans Gunter Drexler

Sonja Eberth

Affiliations

Soon will be listed here.

Abstract

Background: Yin Yang 1 (YY1) is a transcription factor that plays an important role during all stages of B cell differentiation. Several studies reported upregulation of YY1 in B cell derived lymphoma, indicating that it might act as an oncogene. Furthermore, aberrant YY1 expression has been associated with survival in some entities of B cell non-Hodgkin lymphoma (B-NHL), suggesting that YY1 could be a valuable biomarker in B-NHL. However, studies are controversial and methodologically disparate, partially because some studies are based on transcript levels while others rely on YY1 protein data. Therefore, we aimed to investigate the dependence of YY1 protein levels on transcription.

Methods: A panel of human cell lines representing different B-NHL subtypes was used to test for the correlation of mRNA and protein levels which were determined by quantitative PCR and immunoblotting. To analyze mRNA and YY1 protein stability cells were treated with actinomycin-D and cycloheximide, respectively. siRNAs were transfected to knockdown . Kaplan-Meier survival analyses were performed with data from published patient cohorts. Pearson's correlation analyses were assessed and statistical power was examined by Student's t-test.

Results: In the analyzed panel of B-NHL cell lines transcript levels do not correlate with their cellular protein amounts. YY1 protein levels were unaffected by transient block of transcription or by targeting mRNA using siRNA. Additionally, global inhibition of translation up to 48 h did not alter protein levels of YY1, indicating that YY1 is a highly stable protein in B-NHL. Furthermore, in a retrospective analysis of two different B-NHL cohorts, transcript levels had no impact on patients' survival probabilities.

Conclusions: Our results point out the necessity to focus on YY1 protein expression to understand the potential role of YY1 as an oncogene and to unravel its suitability as clinical biomarker in B-NHL.

Citing Articles

Clinical Potential of YY1-Hypoxia Axis for Vascular Normalization and to Improve Immunotherapy.

Meo C, de Nigris F Cancers (Basel). 2024; 16(3).

PMID: 38339244 PMC: 10854702. DOI: 10.3390/cancers16030491.

Yin Yang 1 expression predicts a favourable survival in diffuse large B-cell lymphoma.

Xue T, Lin J, He Y, Li J, Liu Z, Jia Y Heliyon. 2024; 10(2):e24376.

PMID: 38312674 PMC: 10835246. DOI: 10.1016/j.heliyon.2024.e24376.

Dissecting the roles and clinical potential of YY1 in the tumor microenvironment.

Li M, Wei J, Xue C, Zhou X, Chen S, Zheng L Front Oncol. 2023; 13:1122110.

PMID: 37081988 PMC: 10110844. DOI: 10.3389/fonc.2023.1122110.

Role of the Transcription Factor Yin Yang 1 and Its Selectively Identified Target Survivin in High-Grade B-Cells Non-Hodgkin Lymphomas: Potential Diagnostic and Therapeutic Targets.

Vivarelli S, Falzone L, Ligresti G, Candido S, Garozzo A, Magro G Int J Mol Sci. 2020; 21(17).

PMID: 32899428 PMC: 7504013. DOI: 10.3390/ijms21176446.

Cyclin D1 + large B-cell lymphoma with altered CCND1 and BCL-6 rearrangements: a diagnostic challenge.

Gao D, Liu Z Biomark Res. 2019; 7:11.

PMID: 31171971 PMC: 6547582. DOI: 10.1186/s40364-019-0162-2.

References

Kleiman E, Jia H, Loguercio S, Su A, Feeney A . YY1 plays an essential role at all stages of B-cell differentiation. Proc Natl Acad Sci U S A. 2016; 113(27):E3911-20. PMC: 4941496. DOI: 10.1073/pnas.1606297113. View

Zhou H, Mazan-Mamczarz K, Martindale J, Barker A, Liu Z, Gorospe M . Post-transcriptional regulation of androgen receptor mRNA by an ErbB3 binding protein 1 in prostate cancer. Nucleic Acids Res. 2010; 38(11):3619-31. PMC: 2887957. DOI: 10.1093/nar/gkq084. View

Liu H, Schmidt-Supprian M, Shi Y, Hobeika E, Barteneva N, Jumaa H . Yin Yang 1 is a critical regulator of B-cell development. Genes Dev. 2007; 21(10):1179-89. PMC: 1865490. DOI: 10.1101/gad.1529307. View

Matsumura N, Huang Z, Baba T, Lee P, Barnett J, Mori S . Yin yang 1 modulates taxane response in epithelial ovarian cancer. Mol Cancer Res. 2009; 7(2):210-20. PMC: 2675878. DOI: 10.1158/1541-7786.MCR-08-0255. View

Bonavida B, Kaufhold S . Prognostic significance of YY1 protein expression and mRNA levels by bioinformatics analysis in human cancers: a therapeutic target. Pharmacol Ther. 2015; 150:149-68. DOI: 10.1016/j.pharmthera.2015.01.011. View

Ramkumar C, Cui H, Kong Y, Jones S, Gerstein R, Zhang H . Smurf2 suppresses B-cell proliferation and lymphomagenesis by mediating ubiquitination and degradation of YY1. Nat Commun. 2013; 4:2598. PMC: 3801104. DOI: 10.1038/ncomms3598. View

Jeon Y, Lee J . YY1 tethers Xist RNA to the inactive X nucleation center. Cell. 2011; 146(1):119-33. PMC: 3150513. DOI: 10.1016/j.cell.2011.06.026. View

Palko L, Bass H, Beyrouthy M, Hurt M . The Yin Yang-1 (YY1) protein undergoes a DNA-replication-associated switch in localization from the cytoplasm to the nucleus at the onset of S phase. J Cell Sci. 2004; 117(Pt 3):465-76. DOI: 10.1242/jcs.00870. View

Walowitz J, Bradley M, Chen S, Lee T . Proteolytic regulation of the zinc finger transcription factor YY1, a repressor of muscle-restricted gene expression. J Biol Chem. 1998; 273(12):6656-61. DOI: 10.1074/jbc.273.12.6656. View

10.

Lenz G, Wright G, Dave S, Xiao W, Powell J, Zhao H . Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008; 359(22):2313-23. PMC: 9103713. DOI: 10.1056/NEJMoa0802885. View

11.

Sakhinia E, Glennie C, Hoyland J, Menasce L, Brady G, Miller C . Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling. Blood. 2007; 109(9):3922-8. DOI: 10.1182/blood-2006-09-046391. View

12.

Castellano G, Torrisi E, Ligresti G, Nicoletti F, Malaponte G, Traval S . Yin Yang 1 overexpression in diffuse large B-cell lymphoma is associated with B-cell transformation and tumor progression. Cell Cycle. 2010; 9(3):557-63. DOI: 10.4161/cc.9.3.10554. View

13.

Dani C, Blanchard J, Piechaczyk M, El Sabouty S, Marty L, Jeanteur P . Extreme instability of myc mRNA in normal and transformed human cells. Proc Natl Acad Sci U S A. 1984; 81(22):7046-50. PMC: 392073. DOI: 10.1073/pnas.81.22.7046. View

14.

Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth T . A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006; 354(23):2419-30. DOI: 10.1056/NEJMoa055351. View

15.

Vega M, Jazirehi A, Huerta-Yepez S, Bonavida B . Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. J Immunol. 2005; 175(4):2174-83. DOI: 10.4049/jimmunol.175.4.2174. View

16.

Bonavida B, Huerta-Yepez S, Baritaki S, Vega M, Liu H, Chen H . Overexpression of Yin Yang 1 in the pathogenesis of human hematopoietic malignancies. Crit Rev Oncog. 2012; 16(3-4):261-7. DOI: 10.1615/critrevoncog.v16.i3-4.90. View

17.

Liu Y, Beyer A, Aebersold R . On the Dependency of Cellular Protein Levels on mRNA Abundance. Cell. 2016; 165(3):535-50. DOI: 10.1016/j.cell.2016.03.014. View

18.

Zhang Q, Stovall D, Inoue K, Sui G . The oncogenic role of Yin Yang 1. Crit Rev Oncog. 2012; 16(3-4):163-97. PMC: 3386643. DOI: 10.1615/critrevoncog.v16.i3-4.30. View

19.

Arribas J, Castellvi J, Marcos R, Zafon C, Velazquez A . Expression of YY1 in Differentiated Thyroid Cancer. Endocr Pathol. 2015; 26(2):111-8. DOI: 10.1007/s12022-015-9359-6. View

20.

Dong S, Ma X, Wang Z, Han B, Zou H, Wu Z . YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitor. Oncotarget. 2017; 8(25):40583-40593. PMC: 5522268. DOI: 10.18632/oncotarget.17196. View